8-K: Rapport Therapeutics Stockholders Approve Director Elections and Auditor Ratification at 2025 Annual Meeting

Rapport Therapeutics, Inc. announced that its stockholders approved the election of three Class I directors and ratified PricewaterhouseCoopers LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2025, at the 2025 Annual Meeting.

Summary

• Rapport Therapeutics, Inc. held its 2025 Annual Meeting of Stockholders on June 17, 2025.
• As of the record date, April 21, 2025, there were 36,497,555 shares of the Company's common stock outstanding and entitled to vote.
• Stockholders approved the election of Reid Huber, Ph.D., John Maraganore, Ph.D., and Wendy B. Young, Ph.D. as Class I directors, each to serve until the Company's 2028 annual meeting of stockholders.
• For the election of Reid Huber, Ph.D., there were 31,146,580 votes For, 776,312 Withheld, and 1,016,695 Broker Non-Votes.
• For the election of John Maraganore, Ph.D., there were 31,222,571 votes For, 700,321 Withheld, and 1,016,695 Broker Non-Votes.
• For the election of Wendy B. Young, Ph.D., there were 31,783,990 votes For, 138,902 Withheld, and 1,016,695 Broker Non-Votes.
• Stockholders ratified the appointment of PricewaterhouseCoopers LLP (PwC) as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.
• For the ratification of PwC, there were 32,804,657 votes For, 112,489 Against, and 22,441 Abstain.

Sentiment

Score: 7

Explanation: The document reports the successful approval of all proposals at the annual meeting with strong stockholder support, indicating stable corporate governance and no immediate negative surprises. This is a routine positive outcome.

Positives

• All proposed Class I director nominees were approved with significant majorities, indicating strong stockholder support for the board's composition.
• The appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm was overwhelmingly ratified, reflecting confidence in the company's financial oversight and reporting.

Future Outlook

The elected Class I directors, Reid Huber, Ph.D., John Maraganore, Ph.D., and Wendy B. Young, Ph.D., are expected to serve until the Company's 2028 annual meeting of stockholders. PricewaterhouseCoopers LLP is ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

Industry Context

This filing reports routine corporate governance matters, specifically the results of an annual stockholder meeting. Such meetings are standard practice across all publicly traded companies to elect directors and ratify auditors, ensuring compliance with regulatory requirements and maintaining corporate oversight. The outcomes reflect typical stockholder engagement in governance.

Comparison to Industry Standards

• The high approval rates for director elections and auditor ratification are consistent with typical outcomes for well-managed public companies, where such proposals generally pass with strong majority support unless there are significant controversies or activist investor campaigns.
• No specific comparable companies, projects, or results are mentioned in the document to provide a detailed industry-specific comparison.

Corporate Governance

Stakeholder Impact

• Shareholders: The election of directors and ratification of auditors directly impacts shareholders by determining board composition and financial oversight, reinforcing corporate governance. The high approval rates suggest alignment between management and shareholders.

Next Steps

• The newly elected Class I directors will serve until the 2028 annual meeting of stockholders.
• PricewaterhouseCoopers LLP will serve as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

Key Dates

Keywords

Rapport Therapeutics, Annual Meeting, Stockholders, Director Election, Auditor Ratification, PricewaterhouseCoopers LLP, Corporate Governance, SEC Filing, 8-K, RAPP